Buy this biotech stock on pivot to immune disease treatments, Wells Fargo says

Wells Fargo upgraded Biogen to overweight from equal weight and raised its price target to $250 from $200, implying about 41% upside from Friday's close. The bank sees roughly $2.5 billion in adjusted sales from Biogen's lupus and AMR kidney-transplant franchises by 2035, which it believes can more than offset MS erosion. Near-term catalysts over the next 12-18 months from litifilimab, felzartamab and dapirolizumab support a more constructive outlook.

Analysis

The important read-through is not just a re-rating on BIIB, but a potential de-risking of the company’s earnings mix. If immunology/kidney assets can scale even partially as expected, BIIB shifts from a single-engine neurology story to a more balanced late-stage platform, which should compress the “MS-exhaustion” discount embedded in the stock. That matters because the market typically assigns very little value to pipeline optionality until a second franchise becomes visible in real trial data and regulatory milestones.

The second-order winner could be the broader renal-immunology sub-sector: positive BIIB data would validate target biology and accelerate partner appetite for adjacent assets, especially in transplant rejection and autoimmune indications where trial sizes are manageable and commercialization pathways are clearer than in CNS. That creates a spillover effect for other developers with differentiated mechanisms, while putting pressure on incumbents in MS to defend share with price or promotion rather than pure innovation. For BIIB, the key is that incremental growth from these programs is likely to be valued at a higher multiple than declining legacy revenue, so even modest sales inflection can disproportionately lift the equity.

The main risk is timing: the street will pay for catalysts, not long-dated revenue estimates. If the next 12–18 months produce mixed data, regulatory delays, or only incremental efficacy, the market can re-rate BIIB back toward a cash-flow/decline multiple despite the long-dated addressable opportunity. The other tail risk is execution: transplant and autoimmune programs can be biologically promising yet commercially fragmented, with payer scrutiny and physician adoption slowing the path to the modeled revenue base.

Consensus appears to be underestimating how quickly a credible second pillar can change the debate on BIIB’s terminal value. The stock has been treated as a mature neurology name with limited growth, so any data that reinforces both differentiation and durability should create a sharper-than-expected multiple expansion. The setup is asymmetric because downside is partly anchored by existing cash generation, while upside depends on the market simply granting more credit to pipeline optionality.

Key Decisions for Investors

• Add BIIB on weakness ahead of the next 12-18 month catalyst window; target a 15-25% re-rating if trial readouts confirm differentiated efficacy, with downside protected by existing franchise cash flows.
• Buy BIIB 6-12 month call spreads instead of outright equity if implied vol is reasonable; this captures catalyst upside while limiting exposure if data timing slips.
• Pair trade: long BIIB / short a legacy MS-heavy large-cap neuro name to express the thesis that diversified late-stage immunology can outperform declining-single-franchise optics over the next 2-4 quarters.
• Use any post-data gap-up to trim 20-30% of gains unless the company shows clear path to commercial scale; the market may initially overprice early efficacy before de-risking regulatory and adoption hurdles.